Generics
Mylan & Aspen partnership unveils generic Busulfex Injection
5 December 2017 -

Pharmaceutical company Mylan NV (NASDAQ:MYL)(TASE:MYL) and its Aspen (JSE:APN) partner revealed on Monday the availability of the US Food and Drug Administration (FDA) approved Myleran (busulfan) Injection in 60 mg/10 ml (6 mg/ml) single-dose vial in the US leukemia market.

The company stated that the Myleran (busulfan) Injection, 60 mg/10 ml (6 mg/ml) single-dose vial is the generic version of Otsuka Pharmaceutical's Busulfex Injection.

According to the company, the generic Busulfex Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.

Pursuant to its partnership with Aspen, Mylan will commercialise Busulfan Injection in60 mg/10 ml(6 mg/ml) single-dose vial in the US.

For the 12 months ending 30 September 2017, the US sales for Busulfan Injection, 60 mg/10 ml (6 mg/ml) single-dose vial were approximately USD97m, according to IQVIA.

Login
Username:

Password: